Evidence map›Paper›PMID 38474734›Full record

ReviewNutrients2024

Novel Biomarkers of Bone Metabolism.

Sara Fernández-Villabrille, Beatriz Martín-Carro, Julia Martín-Vírgala, Mª Del Mar Rodríguez-Santamaria, Francisco Baena-Huerta, Juan Rafael Muñoz-Castañeda, José Luis Fernández-Martín, Cristina Alonso-Montes, Manuel Naves-Díaz, Natalia Carrillo-López and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
8.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Phosphate and Inflammation in Health and Kidney Disease.International journal of molecular sciences · 2025
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. [Advances in Animal Modeling in the Study of Bone-Vascular Axis Comorbidities].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2025
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Sara Fernández-VillabrilleInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Beatriz Martín-CarroInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-1683-6617
Julia Martín-VírgalaInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Mª Del Mar Rodríguez-SantamariaInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Francisco Baena-HuertaInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Juan Rafael Muñoz-CastañedaRedes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), RICORS2040 (Kidney Disease), 28040 Madrid, Spain.ORCID 0000-0002-9341-0724
José Luis Fernández-MartínInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0003-3455-1778
Cristina Alonso-MontesInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Manuel Naves-DíazInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Natalia Carrillo-LópezInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.ORCID 0000-0002-4227-4144
Sara PanizoInstituto de Investigación Sanitaria del Principado de Asturias (ISPA), 33011 Oviedo, Spain.
Hospital Universitario Central de Asturias · ESInstituto de Investigación Sanitaria del Principado de Asturias · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ES

Funding

Fundación Renal Iñigo Álvarez de Toledo (FRIAT)Instituto de Salud Carlos III CP23/00105; CP23/00058; PI20/00753, PI20/00633, PI22/00195, PI23/00833Instituto de Salud Carlos III Retic REDinREN (RD16/0009/0017),RICORS2040 (RD21/0005/0019 and RD21/0005/0008)Plan de Ciencia, Tecnología e Innovación 2013-2017 y 2018-2022 del Principado de Asturias GRUPIN14-028, IDI-2018-000152, IDI/2021/000080
6 · The paper itself

Abstract

Bone represents a metabolically active tissue subject to continuous remodeling orchestrated by the dynamic interplay between osteoblasts and osteoclasts. These cellular processes are modulated by a complex interplay of biochemical and mechanical factors, which are instrumental in assessing bone remodeling. This comprehensive evaluation aids in detecting disorders arising from imbalances between bone formation and reabsorption. Osteoporosis, characterized by a reduction in bone mass and strength leading to heightened bone fragility and susceptibility to fractures, is one of the more prevalent chronic diseases. Some epidemiological studies, especially in patients with chronic kidney disease (CKD), have identified an association between osteoporosis and vascular calcification. Notably, low bone mineral density has been linked to an increased incidence of aortic calcification, with shared molecules, mechanisms, and pathways between the two processes. Certain molecules emerging from these shared pathways can serve as biomarkers for bone and mineral metabolism. Detecting and evaluating these alterations early is crucial, requiring the identification of biomarkers that are reliable for early intervention. While traditional biomarkers for bone remodeling and vascular calcification exist, they suffer from limitations such as low specificity, low sensitivity, and conflicting results across studies. In response, efforts are underway to explore new, more specific biomarkers that can detect alterations at earlier stages. The aim of this review is to comprehensively examine some of the emerging biomarkers in mineral metabolism and their correlation with bone mineral density, fracture risk, and vascular calcification as well as their potential use in clinical practice.

Indexed as

Chronic Kidney Disease-Mineral and Bone DisorderFractures, BoneOsteoporosisRenal Insufficiency, ChronicVascular CalcificationBiomarkersBone DensityHumansMineralsBiomarkersMineralsbiomarkerbone mineral densitychronic kidney diseasevascular calcification

Identifiers

PMID38474734
PMCPMC10935093
OpenAlexW4392032496

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.